Targeting of the IL-33/Wnt Axis Restricts Breast Cancer Stemness and Metastasis

Scientists investigated the Interleukin-33 (IL-33)/ST2 axis in breast cancer using CRISPR/Cas9, single-cell RNA sequencing, and murine models. IL-33 overexpression enhanced proliferation, migration, and CSC marker expression in 4T1 and MDA-MB-231 cells, whereas ST2 knockdown via CRISPR or adeno-associated virus attenuated tumor growth and metastasis in vivo, reducing CSC frequency.